Victoria Richon PhD Ribon Therapeutics Video Overview httpsyoutube82MDytMTz88Lecture SlidesMuch of the attention on the PARP family has been focused on the polyPARP PARP1 and inhibitors targeting PARP1 have been approved for the treatment of cancer Recently data are emerging regarding the role of the monoPARPs distinct from PARP1 The specific substrates and functions of the twelve monoPARP proteins are currently being elucidated and these recent discoveries indicate that several monoPARPs including PARP7 play important roles in cancer survival pathwaysThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

Anthony Letai MD PhDDanaFarber Cancer Institute Video Overview httpsyoutubeoov2zU7aSJQLecture SlidesThe mitochondrial pathway of apoptosis is probably the mechanism of death in the majority of cases of response of tumors to chemotherapy For many years my laboratory has used a tool BH3 profiling to measure how close a cell is to the threshold of commitment to apoptosis Our work suggests that how primed a cell is for apoptosis is a very important determinant for response to chemotherapy In fact it is probably the most important factor in determining sensitivity to conventional chemotherapy regimens These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

Shannon Stott PhD Massachusetts General Hospital Video Overview httpsyoutubeWNArnUm4i7gLecture SlidesExtracellular vesicles have not seen widespread clinical testing due to limitations in isolation technologies that suffer from low throughput or lack of tumorspecificity To address this we have developed a microfluidic platform the EVHBChip for tumorspecific recovery of EVs using immunoaffinity capture Through this bloodonachip assay we aim to gain a better understanding of when these important tumor derived vesicles are released and how we can exploit their molecular content to better guide patient treatmentThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

Aditya Bardia MD MPHMassachusetts General Hospital Video Overview httpsyoutubeet0fUEWv4bwLecture SlidesEndocrine therapies including aromatase inhibitors represent the backbone of management of estrogen receptorpositive ER breast cancer However despite endocrine therapy a number of patients with ER breast cancer experience disease recurrence Our group along with others has demonstrated the presence of acquired mutations in the ligand binding domain of estrogen receptor ESR1 which can lead to constitutional activation of the estrogen receptor in the absence of ligand estrogen and thereby result in resistance to endocrine therapiesThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

Daniel Haber MD PhD Massachusetts General HospitalLecture SlidesWe will present initial proof of concept applications of a CTCScore analysis for early detection of hepatocellular cancer among patients with underlying chronic liver disease stratification of metastatic prostate cancer patients with poor response to antiandrogen therapy demonstration of early response of melanoma patients to immune checkpoint inhibitors and monitoring druginduced changes in estrogen signaling in women with advanced breast cancer Together these analyses highlight potential clinical applications of RNAbased liquid biopsy measurements in the care of patients with cancerThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

Oladapo Yeku MD PhDMassachusetts General Hospital Video Overview httpsyoutubeX68mu3JHUYLecture SlidesSolid tumor malignancies have yet to benefit from chimeric antigen receptor CAR Tcell therapy compared with hematologic malignancies such as Bcell acute lymphoblastic leukemia and multiple myeloma Despite initially promising preclinical data early clinical trials in ovarian cancer have not yielded meaningful results It is now accepted that the solid tumor microenvironment which includes immunosuppressive immune cells stromal cells and cytokines contributes to active determent of effective Tcell activity We sought to develop strategies to improve CAR Tcell potency and overcome the hostile tumor microenvironment in ovarian cancerThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

David Liu MD MPH MSMassachusetts General HospitalVideo OverviewhttpsyoutubeuiJPj5xMA4Lecture SlidesThe development of immune checkpoint blockade ICB has revolutionized the treatment of cancer However the ability to identify which patients will have durable benefit and to understand how tumors develop resistance to ICB is critical to improving patient management and outcomes Here we present two complementary approaches representing parallel paths to dissecting response and resistance to ICBThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

Ryan Sullivan MD Massachusetts General Hospital Video Overview httpsyoutubeBYmJnsAS1G4Lecture SlidesWhile immune checkpoint inhibitors may be associated with remarkable responses that may be complete and durable most patients will not respond to therapy and a significant minority of patients who do respond will develop disease progression The fields understanding into the underlying mechanisms of resistance to therapy is emerging The objectives of this presentation are to review the clinical data supporting the use of immune checkpoint inhibitors in melanoma as a test case review specific cases of intrinsic and acquired resistance describe the known mechanisms of resistance and propose potential therapies to overcome therapeutic resistanceThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

Laura M Spring MD Massachusetts General HospitalBoston MA USALecture SlidesWe are exploring predictors of response and resistance to neoadjuvant therapies for localized breast cancer including the use of bloodbased biomarkers such as circulating tumor cells and circulating tumor DNA If validated in the neoadjuvant setting this approach could provide an important opportunity to individualize therapy thereby minimizing unnecessary systemic toxicity associated with ineffective therapies and could ultimately improve clinical outcomesThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

Ibiayi DagogoJack MD Massachusetts General Hospital Video Overview httpswwwyoutubecomwatchvzSmIdJsx7iELecture Slides

Aiko Nagayama MD PhD Massachusetts General Hospital Video Overview httpsyoutubeaVxlQBawu4Lecture SlidesTriple negative breast cancer TNBC defined by the lack of hormone receptors and the absence of HER2 overexpression represents 15 to 20 of all breast cancers and has heterogeneous biology with poor prognosis There is no approved targeted therapy for TNBC which calls for a better treatment option Here we report progress in ongoing studies involving a potential biomarkers identified in the profile of serial biopsy TNBC samples from patients who were treated with IMMU132 and b the synthetic lethal target screening by whole genome CRISPRCas9 knockout library in human TNBC cell line modelsThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer

JosephFranses MD PhDMassachusetts General HospitalVideo Overviewhttpsyoutube7k9gnTmf7eULecture SlidesLin28B is an oncofetal RNA binding protein that exerts diverse effects in development metabolism and cancer via interactions with let7 microRNAs and other RNA targets Recent work has demonstrated that Lin28B correlates with worsened outcomes in patients with pancreatic ductal adenocarcinoma PDAC but the functions of Lin28B in PDAC remain to be elucidated We hypothesized that Lin28B plays an active role in PDAC metastasis and drug resistanceThese lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer